NTrans Technologies specializes in non-viral delivery platforms for cell and gene therapies. The company focuses on delivering therapies to specific cells and tissues by leveraging natural mechanisms for cellular uptake.

NTrans Technologies BV

NTrans Technologies

NTrans Technologies BV | 832 followers on LinkedIn. Natural delivery to unlock the full potential of cell and gene therapies | Imagine a world where we conquer cancer and genetic diseases. At NTrans Technologies, we solve key challenges in cell and gene therapy: Delivering life-changing therapies to the right cells and tissues.

We leverage nature’s own mechanisms for cellular uptake to ensure efficient and safe therapeutic delivery.

CEO and co-founder of Predica Diagnostics BV

Marco De Boer (Ph.D., MBA)

CEO NTrans Technologies | Innovation Management | Life Sciences

Ester Weijers

Research Technician

Yali Gal-On

Senior Scientist at Ntrans technologies

Camilo F Muñoz Segovia

We were honored to welcome the Mayor of Leiden Peter Heijkoop to NTrans Technologies at our location in the Leiden BioScience Park, housed in the vibrant ecosystem of Biopartner. This esteemed visit reinforces the dynamic connections between innovative companies and local leadership within our community. The Mayor’s engagement and enthusiasm for the Leiden BioScience Park is inspiring, showcasing a shared vision for advancing science and innovation in our region. His interest in NTrans Technologies reflects the growing support for groundbreaking research and entrepreneurial spirit in the life sciences sector. During the visit, our CEO Ester Weijers had the opportunity to pitch our latest developments, followed by an insightful lab tour. We appreciated the thought-provoking questions he asked, which truly reflect his commitment to understanding and supporting our field. Thank you to the Mayor for a memorable visit, and for his continued support of innovation in Leiden! #Leiden #LeidenBioSciencePark #Biopartner #NTransTechnologies #Biotech #ResearchAndInnovation #ScientificInnovation #LifeSciences

We are excited to share that EUR 10 million have been awarded to NecstGen , NTrans Technologies BV , Leiden University Medical Center , and Divvly to transform Cell and Gene Therapies through the IPCEI Med4Health program. This significant funding will drive our efforts to transform the production of cell and gene therapies, making these life-saving treatments more accessible and affordable for patients in need. Read more about this collaborative effort here: https://lnkd.in/eaURZiu3 #celltherapy #genetherapy #biotechinnovation #CGT #IPCEI

We are searching for talent! We are currently searching for an enthusiastic research technician - molecular biology to join our team. If you have any questions please don't hesitate to ask. #hiring #HLO #LifeSciences #NTransTechnologies #vacancy #carreers

NTrans Technologies participates in BIO-Europe Spring 2024 on 18-20 March in Barcelona. BIO-Europe Spring 2024 is a key event in making connections and building partnerships in the global biopharma community. NTrans looks forward to engaging in meaningful discussions and establishing new partnerships. NTrans Technologies BV developed a non-viral delivery platform for cell and gene therapies building upon CRISPR technology. With our delivery platform we aim to solve a critical bottleneck: safe and scalable delivery of gene-editing therapies.

We're excited to announce the launch of NTrans Technologies brand-new website and visual identity! At NTrans, we are committed to tackling a critical challenge in cell and gene therapy: delivering the gene-editing complex effectively. We prioritize excellence and innovation in our daily endeavors, so that we can make a positive impact for those living with serious diseases. Discover our latest news and learn more about our innovative delivery platform on https://lnkd.in/d_cTYqEF #NTranstechnologies #Websitelaunch #Healthcare #cellandgenetherapy

NTRA

COM:NTRANSTECHNOLOGIES

NTrans Technologies

locale

market

industry

website

crunchbase

linkedin

peer of

competitor of

Metrics